What's Happening?
Novocure has submitted a premarket approval application to the FDA for its Tumor Treating Fields (TTFields) therapy aimed at treating locally advanced pancreatic cancer. This application is supported by the PANOVA-3 trial, which demonstrated a significant improvement in median overall survival for patients treated with TTFields in combination with gemcitabine and nab-paclitaxel, compared to the drug combination alone. The trial results were presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in the Journal of Clinical Oncology.
AD
Why It's Important?
The submission of the PMA application marks a critical step in advancing treatment options for pancreatic cancer, a disease known for its poor prognosis and limited treatment options. If approved, TTFields therapy could offer a new, non-invasive treatment modality that enhances survival rates and quality of life for patients. This development underscores the potential of innovative therapies to address unmet needs in oncology, particularly for aggressive cancers like pancreatic adenocarcinoma.
What's Next?
Novocure anticipates an FDA approval decision in the second half of 2026. The PMA application is expected to be converted to a separate, original PMA for pancreatic cancer treatment. The company continues to focus on expanding the use of TTFields therapy across various solid tumors, with ongoing clinical trials exploring its efficacy in other cancer types.
